Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics that address significant unmet medical needs in ophthalmology, liver disease, and diabetes. Its lead candidate, Tinlarebant (LBS-008), is a novel once-a-day oral therapy targeting autosomal recessive Stargardt disease type 1 (STGD1) and geographic atrophy (GA), an advanced form of age-related macular degeneration. Tinlarebant is designed to reduce retinol binding protein 4 (RBP4) so less retinol is delivered to the eye, reducing vision-damaging toxins. The company is traded on Nasdaq under the ticker BLTE, and Tinlarebant has received Orphan Drug Designation in the U.S., Europe, and Japan as well as Rare Pediatric Disease and Fast Track designations in the U.S.